RVPH
Reviva Pharmaceuticals Holdings Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.12M
P/E Ratio
—
EPS
$-5.48
Beta
0.64
52W High
$23.20
52W Low
$0.59
50-Day MA
$3.69
200-Day MA
$8.16
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical firm focused on developing innovative therapies to address central nervous system (CNS) disorders and other significant health challenges. Its lead candidate, RP5063, offers a novel therapeutic approach for treating schizophrenia and mood disorders, underscored by a proprietary drug delivery platform designed to enhance treatment efficacy. With a robust pipeline and a commitment to meeting critical unmet medical needs, Reviva is strategically positioned for growth in the evolving mental health market as it advances through key clinical development milestones.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-10.10M |
| Operating Margin | 0.00% |
| Return on Equity | -420.00% |
| Return on Assets | -80.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.47 |
| Price-to-Book | 1.06 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -6.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $12.81M |
| Float | $11.17M |
| % Insiders | 1.95% |
| % Institutions | 15.21% |
Analyst Ratings
Consensus ($51.83 target)
1
Strong Buy4
Buy1
HoldData last updated: 4/9/2026